



THUASNE®

THUASNE INVESTS €4M IN FRANCE TO DEVELOP A DIGITALIZED DYNAMIC COMPRESSION POST-CANCER SOLUTION

Thuasne, a global and European player in medical compression devices, announces that it is investing €4 million in Saint-Étienne (France) to develop a digitalized dynamic compression solution integrating motorized pressure on the limb.

Objective: to help improve the management of post-cancer lymphedema, a chronic condition that affects nearly 250 million people worldwide. The project, carried out in a territorial consortium with the Jean Monnet University of Saint-Étienne, is supported by the French State, the Auvergne-Rhône-Alpes Region and Bpifrance as part of the regionalized I-Démo program (France 2030).

SUPPORTING PATIENTS IN THEIR POST-CANCER TREATMENT

Post-cancer lymphedema is a chronic disabling condition that remains widely unknown, with care pathways that are often long and unevenly accessible depending on the territory.

Continuing its expertise and legitimacy in the management of lymphedema – through Mobiderm, the Group's patented technology dedicated to chronic edema – the mid-sized company leverages its industrial experience, scientific expertise, brand awareness and academic network by providing an innovative response to a chronic condition, and pursues its mission: to make patients more autonomous and players in their treatment.

A DIGITAL DEVICE FOR PATIENTS AND CAREGIVERS

This “made in Thuasne” innovation aims to pave the way for a new generation of post-cancer lymphedema management solutions, in a journey that is now complex, long, expensive and insufficiently accessible.

Thanks to a mobile device that the patient carries with them according to the program established by the caregiver, the aim is to adapt the therapy program to the patient's physiological needs in real time. The expected benefits of this new care pathway, made possible by this investment, are greater patient autonomy and freedom, greater accessibility to care, without the constraint of transport and distance, thus facilitating return to work, resumption of sports activity and access to leisure activities. This device will help to better organize follow-up, optimize care time for the physician and caregiver and therefore be more economical for the healthcare system as a whole.

Thanks to the integration of sensors, algorithms and digital interfaces, the device is based on international patents and is part of a digital health model with the following ambitions:

- Improved compliance with treatment;
- A reduction in healthcare costs for Health Insurance thanks to patient autonomy, reduction of home-hospital travel;
- Improved access to treatment, including for patients away from care facilities;
- Improved caregiver medical time.

These benefits will be evaluated through several international clinical and medical-economic studies.

LOCALLY ANCHORED, GLOBALLY AMBITIOUS

With this project, Thuasne reaffirms its roots in Auvergne-Rhône-Alpes (France) and its driving role in the region's health-tech sector, reinforced by a local industrial value chain. It illustrates the convergence between Industry, Research and Technology in the service of a new health economy. This program will contribute to the development of qualified jobs in the fields of R&D, smart textiles, the intersection of microelectronics and digital health. Thuasne's ambition is to develop this innovation, born in the heart of its territory, and to make it shine on its markets and among patients worldwide, particularly in Europe and the United States.



"Investing in tomorrow's healthcare means investing in collective intelligence, technology and territory. This project translates Thuasne's vision: more agile, more accessible and more humane health, from Saint-Étienne to patients around the world."

Elizabeth Ducottet, Chairman of the Thuasne Group.

"This project symbolizes Thuasne's digital transformation and our entry into a new generation of class II connected medical devices. It reflects an increased demand for innovation, quality and compliance, which we will deploy across several ranges in the coming years."

Delphine Hanton, CEO of the Thuasne Group.



About Thuasne®: Founded in 1847, Thuasne® imagines, develops and manufactures medical devices allowing everyone to become actors in their own health. For 6 generations, the Group has been offering concrete, adapted and innovative health solutions in the fields of orthopaedics, medical compression, and sport. With its 2,500 employees, the company generated a turnover of 290 million euros in 2024 of which 50% in international sales. The Group is now present in 110 countries, in particular through its 18 subsidiaries in Europe, North America, Asia and Africa.

corporate.thuasne.com/en

 **Thuasne**
120 rue Marius AUFAN
92300 Levallois - Perret - France
www.thuasne.fr



THUASNE SAS SIREN/RCS Nanterre 542 091 186 – capital €1,950,000 – 120, rue Marius AUFAN 92300 Levallois-Perret (France).

ZMIROV COMMUNICATION

66 rue Jean-Jacques Rousseau
75001 PARIS 1



PRESS CONTACT

ZMIROV COMMUNICATION

Victoria Blin de Laloubie
victoria.blindelaloubie@zmirov.com - +33 6 74 59 06 31



www.zmirov.com